Although these studies measured TILs using company‐based software, not an instrument‐based algorithm like ours, they found substantial variability in CD8+ TILs between individual patients and across the nine types of human cancer although their effects on prognosis are not described [3]. The gene discussed is CD8A; the disease is cancer.